These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

888 related items for PubMed ID: 17017818

  • 1. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.
    Gao K, Muzina D, Gajwani P, Calabrese JR.
    J Clin Psychiatry; 2006 Sep; 67(9):1327-40. PubMed ID: 17017818
    [Abstract] [Full Text] [Related]

  • 2. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
    Hirschfeld RM, Weisler RH, Raines SR, Macfadden W, BOLDER Study Group.
    J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
    [Abstract] [Full Text] [Related]

  • 3. Typical and atypical antipsychotics in bipolar depression.
    Gao K, Gajwani P, Elhaj O, Calabrese JR.
    J Clin Psychiatry; 2005 Nov; 66(11):1376-85. PubMed ID: 16420074
    [Abstract] [Full Text] [Related]

  • 4. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.
    Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR.
    J Clin Psychiatry; 2011 Aug; 72(8):1063-71. PubMed ID: 21034695
    [Abstract] [Full Text] [Related]

  • 5. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR, Theodore G.
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [Abstract] [Full Text] [Related]

  • 6. Use of atypical antipsychotics in refractory depression and anxiety.
    Nemeroff CB.
    J Clin Psychiatry; 2005 Jun; 66 Suppl 8():13-21. PubMed ID: 16336032
    [Abstract] [Full Text] [Related]

  • 7.
    Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T.
    ; 2011 09. PubMed ID: 22132426
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
    Suppes T, McElroy SL, Sheehan DV, Hidalgo RB, Cosgrove VE, Gwizdowski IS, Feldman NS.
    J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
    [Abstract] [Full Text] [Related]

  • 9. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G, Naja WJ, Pelissolo A.
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [Abstract] [Full Text] [Related]

  • 10. Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review.
    Rakofsky JJ, Dunlop BW.
    J Clin Psychiatry; 2011 Jan; 72(1):81-90. PubMed ID: 21208580
    [Abstract] [Full Text] [Related]

  • 11. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
    Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR.
    J Clin Psychiatry; 2008 Feb; 69(2):302-9. PubMed ID: 18211129
    [Abstract] [Full Text] [Related]

  • 12. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study.
    Maina G, Albert U, Rosso G, Bogetto F.
    J Clin Psychiatry; 2008 Apr; 69(4):609-16. PubMed ID: 18294024
    [Abstract] [Full Text] [Related]

  • 13. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
    Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE, Janavs J, Rogers J, Gonzalez R, Shivakumar G, Suppes T.
    J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
    [Abstract] [Full Text] [Related]

  • 14. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [Abstract] [Full Text] [Related]

  • 15. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD008121. PubMed ID: 21154393
    [Abstract] [Full Text] [Related]

  • 16. Comparison of antidepressant use between subjects with bipolar disorder and major depressive disorder with or without comorbid anxiety.
    Schaffer A, Cairney J, Veldhuizen S, Cheung A, Levitt A.
    J Clin Psychiatry; 2007 Nov 08; 68(11):1785-92. PubMed ID: 18052573
    [Abstract] [Full Text] [Related]

  • 17. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M.
    J Clin Psychiatry; 2009 Oct 08; 70(10):1424-31. PubMed ID: 19906346
    [Abstract] [Full Text] [Related]

  • 18. The role of atypical antipsychotics in bipolar depression and anxiety disorders.
    McIntyre R, Katzman M.
    Bipolar Disord; 2003 Oct 08; 5 Suppl 2():20-35. PubMed ID: 14700010
    [Abstract] [Full Text] [Related]

  • 19. Effect of comorbid anxiety on treatment response in bipolar depression.
    Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, Xu W, Corya S.
    J Affect Disord; 2007 Dec 08; 104(1-3):137-46. PubMed ID: 17512607
    [Abstract] [Full Text] [Related]

  • 20. Impact of comorbid anxiety disorders and obsessive-compulsive disorder on 24-month clinical outcomes of bipolar I disorder.
    Kim SW, Berk L, Kulkarni J, Dodd S, de Castella A, Fitzgerald PB, Amminger GP, Berk M.
    J Affect Disord; 2014 Sep 08; 166():243-8. PubMed ID: 25012437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.